Please assess the completion status of the following clinical trial:

Trial Title: QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female patients, age 30 to 65 years of age,~2. Clinical diagnosis of type 2 diabetes at least 6 months prior to enrollment,~3. Stable on current treatment consisting of either human or recombinant multi-dose insulin therapy (MDI) with metformin,~4. HbA1c of 7.5-12%, inclusive,~5. Demonstrated willingness to check and record blood glucose readings at seven time points as instructed in the study protocol.~6. Medically controlled hypertension, at least on one anti-hypertensive~7. Medically controlled hyperlipidemia, on or off cholesterol-lowering therapy~8. BMI \>30~Exclusion Criteria:~1. Pregnancy or Lactating,~2. Type 1 Diabetes,~3. Concomitant use of forbidden medications: prescription sympathomimetics (within seven days of screening), ergot alkaloid derivatives, and anti-migraine medications,~4. Patients with history of drug or alcohol abuse within 3 years of enrollment,~5. Patients at risk for hypotension, including those who have:~   * Recent blood donation within 30 days of enrollment,~  * A history of syncopal migraines, or~  * Significant gastroparesis or orthostatic hypotension which could signify advanced autonomic neuropathy.~6. Uncontrolled mental illness especially with history of psychosis,~7. Any severe, uncontrolled or terminal medical condition which the investigator feels would interfere with the patient's ability to participate and comply with the study protocol,~8. Serum creatinine \>1.4mg/dL in females or \>1.5mg/dL in males that would preclude the patient from taking metformin,~9. LFTs elevated \>3x upper limit of normal,~10. Patients working rotating, varying or night shifts, or~11. Patient with circumstances or abnormalities (e.g. blindness or history of non-compliance) that would interfere with the interpretation of safety or efficacy data or completion of the study.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Metformin + Insulin (Type: NO_INTERVENTION): 5 patients to continue on usual type 2 diabetic treatment consisting of 70/30 insulin, metformin and exercise and nutrition counseling.
- QR-Bromocriptine +metformin+insulin (Type: EXPERIMENTAL): study drug add-on the usual therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).